Replies to post #195866 on Biotech Values

[DewDiligence]

EXAS +13% today—but -75% from 12m high—on 3Q15 results, which feature $12.8M revenue and 34K Cologuard tests (many of which were not reimbursed):

http://finance.yahoo.com/news/cologuard-growth-trajectory-increases-34-090000485.html